Memantine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Memantine: From Alzheimer’s Disease to Migraine Disorder
One-Sentence Summary
Memantine is an NMDA receptor antagonist originally developed for moderate-to-severe Alzheimer’s disease. The TxGNN model’s top-ranked prediction was pulmonary hypertension, but that signal is unsupported by any real-world evidence. The second-ranked prediction — Migraine Disorder — carries a near-identical TxGNN score and is backed by 2 clinical trials and 20 publications, including a completed Phase 3 RCT, a meta-analysis, and a systematic review, making it the far more actionable candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer’s disease (moderate to severe) — based on established drug knowledge; not present in this evidence pack (no EU/TW licenses on file) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.52% (rank 5,318 of all predictions) |
| Evidence Level | L1 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Note on candidate selection: TxGNN’s rank-1 prediction, pulmonary hypertension (score 99.54%), has no clinical trials and only tangential literature (one mechanistic paper on glutamate/NMDA signaling in metabolism, and one PK study of a different nitrate-derivative compound, MN-08, whose relevance to memantine itself is questionable). Migraine — rank 2 by a statistically negligible score difference — has substantially stronger, direct clinical evidence and is therefore the focus of this report.
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on established pharmacological knowledge, memantine is a non-competitive NMDA receptor antagonist, originally approved for moderate-to-severe Alzheimer’s disease, where it works by reducing glutamate-mediated excitotoxicity in the CNS.
This same mechanism is directly relevant to migraine pathophysiology. Glutamatergic overactivity and NMDA receptor signaling are implicated in cortical spreading depression and central sensitization — two core processes in migraine generation. Multiple independent reviews (e.g., Hoffmann & Charles 2018; Podkowa et al. 2023) identify glutamate signaling as a validated therapeutic target for migraine, providing a coherent mechanistic bridge between memantine’s known pharmacology and this new indication.
Clinically, this rationale has already been tested: case series and open-label studies date back to 2007–2009, a placebo-controlled RCT was published in 2016, and by 2021 two independent groups (a systematic review and a meta-analysis of RCTs) had synthesized the accumulated evidence. A completed Phase 3 RCT (NCT04698525) directly compared memantine to sodium valproate — an established first-line migraine prophylactic — for episodic migraine prevention. Together, this constitutes a plausible, mechanistically grounded, and clinically tested repurposing hypothesis, though the underlying trials remain small.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04698525 | Phase 3 | Completed | 33 | Head-to-head comparison of memantine vs. sodium valproate for prophylactic treatment of episodic migraine; direct efficacy comparison against an established Level A prophylactic agent, though limited by small sample size. |
| NCT02670161 | Phase 4 | Enrolling by invitation | 3,300 | Broad EMR-based pragmatic registry across 10 common neurological disorders at NorthShore University HealthSystem; not designed specifically to evaluate memantine for migraine (low relevance). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33961371 | 2021 | Meta-Analysis of RCTs | Clinical Neuropharmacology | Pooled analysis of randomized controlled studies evaluating memantine’s efficacy in migraine; synthesizes prior RCT evidence base. |
| 34352118 | 2021 | Systematic Review | Headache | Systematic assessment of efficacy and safety of memantine for prophylactic treatment of episodic migraine. |
| 40978493 | 2025 | Network Meta-Analysis | Frontiers in Pharmacology | Compares oral preventive migraine medications, including memantine, across efficacy and safety in adults 18–65. |
| 26638119 | 2016 | RCT (Double-Blind, Placebo-Controlled) | Headache | Randomized controlled trial testing memantine for prophylaxis of migraine without aura, building on earlier uncontrolled findings. |
| 17901918 | 2007 | Retrospective Study | Journal of Headache and Pain | Retrospective characterization of memantine’s efficacy as preventive therapy in patients with frequent migraine. |
| 19031499 | 2008 | Open-label Study | Headache | Assessed efficacy and tolerability of memantine in preventive treatment of refractory migraine. |
| 19280698 | 2009 | Open-label/Pilot Study | Headache | Early pilot evidence for memantine in preventive treatment of migraine and refractory migraine. |
| 36869904 | 2023 | Review | Naunyn-Schmiedeberg’s Archives of Pharmacology | Reviews NMDA receptor antagonists memantine and ketamine as anti-migraine agents, summarizing published trial evidence. |
| 29508147 | 2018 | Review | Neurotherapeutics | Reviews glutamate and its receptors, including NMDA, as therapeutic targets for migraine, supporting the mechanistic rationale. |
| 34510445 | 2021 | Commentary/Opinion | Headache | “Memantine for migraine—Big promise but little evidence” — cautionary expert commentary highlighting the gap between mechanistic promise and confirmatory trial data. |
EU Market Information
No EU marketing authorizations are currently on record for memantine in this dataset (market status: Not Marketed, 0 licenses).
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and drug interaction data are all flagged as data gaps in this evidence pack — DG001, Blocking severity — and must be sourced from the official TFDA/EMA label before any clinical decision.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is strong and consistently reinforced across nearly two decades of literature, culminating in a completed Phase 3 RCT, a systematic review, and a meta-analysis (L1 evidence). However, the largest controlled trial enrolled only 33 patients, and a 2021 expert commentary explicitly cautions that “promise” outpaces “evidence” — so this is not yet a Go, but the evidence base is too substantial to Hold.
To proceed, the following is needed:
- TFDA/EMA label data (key warnings, contraindications, DDI) — currently a Blocking data gap (DG001)
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- A larger, adequately powered confirmatory Phase 3 RCT for episodic/chronic migraine prophylaxis
- Regulatory pathway assessment, since memantine currently holds no marketing authorization in this jurisdiction
- Re-evaluation of the pulmonary hypertension signal (rank 1) once independent, drug-specific (not MN-08 analog) evidence becomes available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.